Summary by Futu AI
Recursion Pharmaceuticals has filed a prospectus supplement on December 17, 2024, to register 3,498,393 shares of its Class A common stock for resale. These shares were issued to Tempus Labs as payment for the 2024 annual license fee under their previously announced Master Agreement.The share offering was conducted under an exemption from registration under the Securities Act of 1933. The registration was made through an automatic "shelf" Registration Statement on Form S-3ASR, which was originally filed with the SEC on May 10, 2022. Legal opinion regarding the legitimacy of the resale shares was provided by Wilson Sonsini Goodrich & Rosati, P.C.
Comment(0)
Reason For Report